Arbour KC, et al. - In a phase 1 study of pulse/continuous-dose erlotinib, no patient indicated disease progression in the central nervous system (CNS). Authors, in this expansion cohort of the phase 1 study, investigated the same regimen in a cohort of individuals with epidermal growth factor receptor (EGFR)–mutant lung cancers with untreated brain metastases. Findings revealed that pulse/continuous-dose erlotinib resulted in a 74% overall response rate and a 75% response rate in brain metastases in patients with EGFR-mutant lung cancers and untreated brain metastases. CNS control persisted even after progression elsewhere. Despite not improving progression-free survival or delaying the emergence of EGFR T790M, this regimen prevented progression in the brain and could be useful in situations in which CNS control is critical.